Journal article

Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant

Ofure Obazee, Christina Justenhoven, Stefan Winter, Jenny Chang-Claude, Anja Rudolph, Petra Seibold, Dieter Flesch-Janys, Ulf Hannelius, Jingmei Li, Keith Humphreys, Per Hall, Graham Giles, Gianluca Severi, Laura Baglietto, Melissa Southey, Sylvia Rabstein, Volker Harth, Anne Lotz, Beate Pesch, Thomas Bruening Show all

BREAST CANCER RESEARCH AND TREATMENT | SPRINGER | Published : 2013

Abstract

17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) plays an important role in the biosynthesis of 17β-estradiol. The current study aimed at confirming the reduced risk of breast cancer in carriers of the non-synonymous HSD17B1_937_A>G (rs605059) polymorphism who used any hormone replacement therapy (HRT) for 10 years or longer. We performed an independent association study using four breast cancer case-control studies from Australia, Germany, and Sweden. In all, 5,777 cases and 8,189 age-matched controls of European descent were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and TaqMan. Risk estimates were calculated by interaction ana..

View full abstract

Grants

Awarded by Federal Ministry of Education and Research (BMBF) Germany


Awarded by EU


Awarded by Deutsche Krebshilfe e.V


Awarded by BMBF Germany


Awarded by National Institutes of Health


Awarded by Swedish Cancer Society


Awarded by NHMRC


Funding Acknowledgements

The authors acknowledge support of the Robert Bosch Foundation, Stuttgart, Germany, and the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0, 01KW0114. OO was supported by the 7FP EU Marie Curie Initial Training Network "FightingDrugFailure'' (GA238132). The MARIE study was supported by the Deutsche Krebshilfe e.V., grant number 70-2892-BR I and the Hamburg Cancer Society. The MARIE-GENICA project was funded by BMBF Germany grants 01KH0401, 01KH0402, 01KH0410, and 01KH0411. SASBAC was supported by National Institutes of Health (RO1 CA58427) and Marit and Hans Rausing's Initiative Against Breast Cancer. KC was supported by the Swedish Cancer Society (5128-B07-01PAF). MCCS is supported by Cancer Council Victoria and by NHMRC (grants 209057, 251533, 396414, 504711, and 504715).